Teva fills CFO position as Desheh steps up to CEO

Chutes and Ladders

Welcome to this week's Chutes and Ladders, our roundup of hirings and firings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter) or Emily Mullin (email | Twitter) and we will feature it here at the end of each week.

Teva fills CFO position as Desheh steps up to CEO

After Jeremy Levin's resignation last week, Teva ($TEVA) is still rearranging its executive pieces, this time filling the empty CFO spot that Eyal Desheh left when he became the Israeli company's interim CEO. Teva's Kobi Altman, formerly the head of global accounting, VP of finance and most recently SVP and CFO of the company's American arm, will serve as the acting CFO. More

Teva Pharmaceuticals
Former CFO Eyal Desheh replaced Jeremy Levin as acting president and CEO.


Coronado
Kevin Horgan joined Coronado as chief medical officer.


Biotech

Coronado Biosciences brought on Kevin Horgan as its chief medical officer. Previously, Horgan was senior vice president and chief medical officer at Soligenix ($SNGX), as well as the head of internal medicine at GE Healthcare ($GE). He has also served as vice president of clinical immunology at Janssen and senior director of clinical research at Merck ($MRK). Release

Alba Therapeutics tapped Wendy Perrow to be the company's new chief executive officer. Release

Former Merck exec Michael Mendelsohn joined the board of directors at Regado Biosciences. Release

Stellar Biotechnologies brought on Kathi Niffenegger as its chief financial officer and Catherine Brisson as its chief operations officer. Release

iBio appointed Carlos Picosse as chief executive officer and Renato Lobo as chief medical officer of the company's Brazilian subsidiary, iBio Brazil. Release

Selvita appointed Miroslawa Zydron as a member of its management board and the director of its chemistry division and Krzysztof Brzozka as its executive vice president and chief scientific officer. Release

Michael Berendt replaced Graeme McRae as CEO of Bioniche Life Sciences. Release

AGTC, a clinical stage biotechnology company, hired two new management team members, Daniel Menichella and Frank Sprecher. Both bring previous leadership experience in the biopharma industry. Daniel Menichella will serve as AGTC's vice president and chief business officer, and Frank Sprecher joins as the company's project director. Release

Dinesh Patel, co-founder of vSpring Capital (now Signal Peak Ventures), has joined the board of directors for Utah-based Tute Genomics. Release

Colin Goddard has joined Endocyte's ($ECYT) board of directors. Goddard is CEO and chairman of Coferon and director of biotechs Agendia and PanOptica. Release

> Michael Kitt joined Afferent Pharmaceuticals as chief medical officer. Release

> Amarantus Bioscience Holdings has appointed David Lowe to its board of directors. Lowe is president and CEO of NeuroAssets. Release

Pharma

> Antares Pharma brought on Bruce Freundlich as the company's senior vice president, medical. Release

> A.P. Pharma appointed Paul Marshall as its senior vice president of technical operations and Brian Drazba as vice president of finance and chief financial officer. Release

> PharMerica appointed Christopher Schaefer as its senior vice president of corporate development. Release

Medicines360 named Pamela Weir as its chief operating officer. Weir has had similar positions at Bayer and Sanofi-Aventis. Release

> Basilea Pharmaceutica brought on Donato Spota as its chief financial officer. Release

KV Pharmaceutical has appointed Janet Vergis to its board of directors. Vergis is a former executive for Johnson & Johnson ($JNJ), where she served as president of Janssen Pharmaceuticals, and she currently serves as the executive-in-residence at Warburg Pincus. Release

Acusphere has appointed William Ramage chief development officer. Previously, Ramage served as an executive consultant at the company. Release

Medical Devices

> AdvaMed named Donald May its executive vice president of payment and healthcare delivery policy. Release

CRO

> Celerion appointed Clayton Dehn as executive director of metabolic diseases. Dehn has led successful metabolic programs at two leading CROs, and served as director of clinical research and development at a startup biotech company. Release

> Phlexglobal has appointed Steven Kent as nonexecutive chairman. Previously, Kent was a member of Parexel's ($PRXL) operational board. Release

Vaccines

> Gerald Moeller has been appointed as vice president of French Genticel's supervisory board. Moeller has been an investment adviser at HBM Partners in Switzerland since 2002 and chairs the supervisory boards of several health sector companies. Release

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.